MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: ...

The exciting potential of novel medical technologies — particularly devices for diagnosis and treatment — to transform health care is just emerging. As devastating as the COVID-19 pandemic was, the ...

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a ...

Medical professionals don’t pursue careers in healthcare out of a love of data entry, but it’s an inescapable daily reality for most, taking time away from focused care and consultations with patients ...

Sequel Med Tech has a plan to explore a new type of ultra-concentrated and fast-acting insulin, to see how it may work with its automated pump and potentially offer a longer-lasting system for people ...

Cochlear implant surgery helps people with severe hearing loss by placing an electronic device inside the inner ear. To reach ...

CELZ-201-DDT is a proprietary allogeneic regenerative therapy designed to target the underlying pathology of DDD. Administered via ultrasound-guided injection, it offers a minimally invasive, ...

MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE ...

The European med tech industry has called for patient access to innovative technologies to be preserved under a new legislative proposal. Last week, the European Council agreed to start negotiations ...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care through the power of portable, semiconductor-based ...

April data and first quarter earnings reports show remarkable resilience in med tech, even as other sectors continue to suffer in response to tariffs and changing regulations. Not that tariffs proved ...